Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Merck (MRK) Outperforms Industry This Year So Far: Here's Why
12:31pm, Thursday, 19'th May 2022 Zacks Investment Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
Pfizer (PFE) Gets EUA for Use of Comirnaty Booster in Children
02:07pm, Wednesday, 18'th May 2022 Zacks Investment Research
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.
Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints
03:33pm, Tuesday, 17'th May 2022 Zacks Investment Research
Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.
12 stocks to consider for the next leg of the bull market
07:45pm, Saturday, 14'th May 2022 MarketWatch
These companies are typically uncorrelated to indexes, giving investors a chance to outperform.
These High-Yield Dividend Stocks Are Growing at Blazing Speeds
03:07pm, Thursday, 12'th May 2022 The Motley Fool
These two stocks can provide income investors with dividend yields that are double what the broader market is offering.
CNBC's Final Trades: Charles Schwab And These 3 Medical Stocks
11:52am, Thursday, 12'th May 2022 Benzinga
On CNBC’s “Halftime Report Final Trades,” Karen Firestone of Aureus Asset Management said Charles Schwab Corporation (NYSE: SCHW) is trading at 14 times next year’s earnings. “If rates go u
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
06:08pm, Wednesday, 11'th May 2022 Zacks Investment Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
2 Cash-Rich Dividend Stocks To Counter Growing U.S. Recession Risks
05:48am, Wednesday, 11'th May 2022 Investing.com
5 Safe And Cheap Dividend Stocks To Invest In (May 2022)
01:30pm, Saturday, 07'th May 2022 Seeking Alpha
This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying, and are offering large discounts to their historical norms.
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2022 Update
05:44am, Saturday, 07'th May 2022 Seeking Alpha
Ken Fisher’s 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Find more details here...
Top Analyst Reports for Comcast, CME & Charter Communications
10:36pm, Friday, 06'th May 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), CME Group Inc. (CME), and Charter Communications, Inc. (CHTR).
Drug companies are making an accounting change after the SEC cracked down on Biogen
05:07pm, Friday, 06'th May 2022 MarketWatch
Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in w
Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates
03:11pm, Friday, 06'th May 2022 Zacks Investment Research
Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.
The Nasdaq, S&P 500 And Dow Took A Big Dive In April
08:15pm, Friday, 29'th Apr 2022 Benzinga
Markets finished off the month of April down big amid a mixed first-quarter earnings season. For the month, the Nasdaq fell 15%, the S&P 500 fell 10.2% and the Dow fell 6.4%.
On Thursday, the Commer
AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates
07:12pm, Friday, 29'th Apr 2022 Zacks Investment Research
AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.
